Savara Inc
Savara Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program is MOLBREEVI (molgramostim inhalation solution), an inhaled biologic being developed for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and delivered through a proprietary eFlow Nebulizer System.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaMOLBREEVI is Savara's inhaled biologic candidate for autoimmune PAP.
Asiakkaat
Savara does not yet sell commercial products; its future customers would be patients with autoimmune PAP and the physicians and specialty centers that diagnose and treat this rare lung disease. If approved, access and adoption would also depend on payers and reimbursement decision-makers because the therapy would be used in a specialized, high-acuity setting.
Patients with autoimmune pulmonary alveolar proteinosis who would use MOLBREEVI if approved.
Pulmonologists and specialty centers that diagnose, prescribe, and monitor treatment.
Insurers and health systems that influence patient access and commercial uptake.
Potential collaborators for commercialization outside the U.S. and selected markets.
Strategia
Savara's strategy is centered on advancing MOLBREEVI through regulatory approval and building a focused commercialization model for rare respiratory disease. The company aims to serve key prescribing physicians and centers directly in the U.S., while considering partnerships outside the U.S. to extend reach and reduce execution burden.
Commercial value depends on obtaining approval for the sole product candidate.
A rare-disease launch requires specialized sales, access, and patient support infrastructure.
International collaboration can extend reach while limiting direct operating complexity.
Maantiede
Savara is headquartered in the United States, with its principal office in Langhorne, Pennsylvania, and a majority of employees working remotely. The company is pursuing approval and eventual commercialization in the U.S., EU, and the UK, with additional markets considered where regulatory and economic conditions support expansion.
Riskit
Savara is highly dependent on the clinical, regulatory, and eventual commercial success of a single product candidate, so any setback could materially affect the business. The company also faces financing, execution, cybersecurity, and debt covenant risks that are common for development-stage biopharma companies but especially important because it has no product revenue.
- Dependence on MOLBREEVIVaikutus: KriittinenTodennäköisyys: Korkea
The company has one product candidate, so failure in development or approval would leave no commercial portfolio.
Kohdistuu - Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
FDA or other regulators may delay, request changes, or deny approval, pushing out commercialization.
Kohdistuu - Financing riskVaikutus: KorkeaTodennäköisyys: Korkea
The company has no product revenue and may need additional capital to fund development and launch.
Kohdistuu - Commercial launch executionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Rare-disease commercialization requires specialized sales, access, and reimbursement capabilities.
Kohdistuu: U.S. specialty market
- Cybersecurity and remote-work riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
A distributed workforce and virtual operations increase exposure to phishing, malware, and data loss.
Kohdistuu: Remote employees and cloud/IT systems
- Debt covenant riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Loan covenants could accelerate repayment or restrict operations if not met.
Kohdistuu: Hercules Loan Agreement
Kirjanpito
Harkinnanvaraiset erätUntil approval and launch, the income statement is dominated by R&D and G&A rather than sales recognition.
Vaikutus: Revenue remains zero until commercialization begins
Loan fees, discounts, and covenant-related terms affect interest expense and balance sheet carrying values.
Vaikutus: Amortization and extinguishment gains/losses can affect net loss
European vendors and subsidiaries create FX exposure in local currencies.
Vaikutus: FX gains/losses flow through other income (expense), net
Cash management and investment maturities affect interest income and liquidity presentation.
Vaikutus: Can influence non-operating income and cash flow classification
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Palvella Therapeutics, Inc
PVLA · Pharmaceutical Preparations
Palvella Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare genetic skin and vascular disorders.
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
Travere Therapeutics, Inc.
TVTX · Pharmaceutical Preparations
Travere Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for rare diseases, with commercial products in kidney and metabolic disorders.
Spero Therapeutics, Inc.
SPRO · Pharmaceutical Preparations
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Zevra Therapeutics, Inc
ZVRA · Pharmaceutical Preparations
Zevra Therapeutics is a U.S.-based rare-disease pharmaceutical company focused on developing, commercializing, and expanding therapies for small patient populations with high unmet need.
Päivitetty: 24.9.2026